Comparing SSRI treatment costs for depression using retrospective claims data: The role of nonrandom selection and skewed data

Value in Health

Volumn 3, Issue 3, 2000, Pages 208-221

  Berndt, Ernst R ^a,e   Russell, James M ^b   Miceli, Robert ^c   Colucci, Salvatore V ^d   Xu, Yikang ^d   Grudzinski, Amy N ^c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c PFIZER INC   (United States)

^d IPR Data Solutions LLC   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Costs; Depression; Pharmacoeconomics; Retrospective claims data; SSRIs

Indexed keywords

FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; DATA ANALYSIS; DEPRESSION; DRUG COST; FEMALE; HEALTH CARE COST; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0033880845     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2000.33001.x     Document Type: Article

References (43)

1. Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care. JAMA 1996;275:1897-902.
2. Simon G, Wagner E, Vonkorff M. Cost-effectiveness comparison using 'real world' randomized trials: The case of new antidepressant drugs. J Clin Epidemiol 1995;48:363-73.
3. Egberts AC, Lenderink AW, de Koning FH, Leufkens HG. Channeling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatment. J Clin Psychopharmacol 1997;17(3):149-55.
4. Thompson D, Buesching D, Gregor KJ, Oster G. Patterns of antidepressant use and their relation to costs of care. Am J Man Care 1996;2:1239-46.
5. Crown WH, Obenchain RL, Englehart L, et al. The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization. Statist Med 1998;17:1943-58.
6. Russell JM, Berndt ER, Miceli R, et al. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline. Am J Man Care 1999; 5:597-606.
7. Hylan TR, Crown WH, Meneades L, et al. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis. J Affect Disord 1998;47:71-9.
8. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. J Int Med Res 1995;23: 395-412.
9. Skaer TL, Sclar DA, Robison LM, et al. Economic evaluation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression. Current Therapeutic Research 1996;56:556-67.
10. Simon GE, Fishman P. Cost implications of initial antidepressant selection in primary care. Pharmacoeconomics 1998;13:61-70.
11. Forder J, Kavanagh S, Fenyo A. A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. J Affect Disord 1996;38:97-111.
12. Crown WH, Hylan TR, Meneades L. Antidepressant selection and use, and healthcare expenditures. Pharmacoeconomics 1998;13:435-48.
13. John DN, Wright T, Berti C. Is there an economic advantage in the use of SSRIs over TCAs in the treatment of depression? J Serot Res 1996;4:225-35.
14. Woods SW, Rizzo JA. Cost-effectiveness of antidepressant treatment reassessed. B J Psych 1997;170: 257-63.
15. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994; 16:715-30.
16. Sclar DA, Skaer TL, Robison LM, et al. Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis. J Clin Psych 1998;59:13-7.
17. Croghan TW, Lair TJ, Engelhart L, et al. Effect of antidepressant therapy on health care utilization and costs in primary care. Psychiatric Services 1997;48:1420-6.
18. Kessler RC, McGonagle KA, Swartz M, et al. Sex and depression in the National Comorbidity Survey I. Lifetime prevalence, chronicity and recurrence. J Affect Disord 1993;29:85-96.
19. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psych 1993;54:405-18.
20. American Psychiatric Association. Practice guideline for major depressive disorder in adults. Am J Psychiatry 1993;150:1-26.
21. Baldessarini RJ. Current Status of antidepressants: clinical pharmacology and therapy. J Clin Psych 1989;50:117-26.
22. Regier DA, Hirschfeld RMA, Goodwin FK, et al. The NIMH depression awareness, recognition, and treatment program: structure, aims, and scientific basis. Am J Psychiatry 1988;145:1351-7.
23. Regier DA, Narrow WE, Rae DS, et al. The de facto mental and addictive disorders service system. Arch Gen Psychiatry 1993;50:85-93.
24. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998;17:283-95.
25. Newhouse JP. Health economics and health econometrics. Am Econ Rev 1986;77:269-74.
26. Wilde MI, Benfield P. Fluoxetine. A pharmacoeconomic review of its use in depression. Pharmacoeconomics 1998;13:543-61.
27. Simon GE, Katzelnick DJ. Depression, use of medical services and cost-offset effects. J Psychosomatic Res 1997;42(4):333-44.
28. Heckman J. Sample selection bias as a specification error. Econometrica 1979;47:153-62.
29. Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. J Educ Psych 1974;66:688-701.
30. Duan N, Manning WG, Jr, Norris CN, Newhouse JP. A comparison of alternative models for the demand for medical care. J Bus Econ Stat 1983;1: 115-26.
31. Hay JW, Olsen RJ. Let them eat cake: a note on comparing alternative models of the demand for medical care. J Bus Econ Stat 1984;2:279-82.
32. Duan N, Manning WG, Jr, Norris CN, Newhouse JP. Choosing between the sample-selection model and the multi-part model. J Bus Econ Stat 1984;2: 283-9.
33. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assn 1996;91 (434):444-55.
34. Leung SF, Yu S. On the choice between sample selection and two part models. J Econometrics 1996; 72:197-229.
35. Belsley D, Kuh E, Welsch R. Regression Diagnostics. Identifying Influential Data and Sources of Collinearity. New York: John Wiley & Sons, 1980.
36. Greene WH. Econometric Analysis (2nd ed.). New York: MacMillan Publishing Co, 1994.
37. Mullahy J. Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ 1998;17:247-81.
38. McKelvey RD, Zavoina W. A statistical model for the analysis of ordinal level dependent variables. J Math Soc 1975;4:103-20.
39. Little RAJ. A note about models for selectivity bias. Econometrica 1985;53(6): 1469-74.
40. Hylan TR, Crown WH, Meneades L, Heiligstein JH, et al. SSRI antidepressant drug use patterns in a naturalistic setting. A multivariate analysis. Med Care 1999;37(4):AS36-44.
41. Petri H, Heerdink R, Leufkens HG, et al. Channeling of antidepressant drugs to patients with cardiovascular disease. Post-Marketing Surveillance 1991;5:159-67.
42. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991;10:577-81.
43. Avila MH, Walker AM, Romieu I, et al. Choice of non-steroidal anti-inflammatory drug in persons treated for dyspepsia. Lancet 1988;332:556-9.